Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

E. Alves; S. Taifour; R. Dolcetti; J. Chee; A.K. Nowak; S. Gaudieri; P. Blancafort

doi:10.1016/j.omtm.2021.04.009

Back

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

Journal article

Open access

Peer reviewed

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

E. Alves, S. Taifour, R. Dolcetti, J. Chee, A.K. Nowak, S. Gaudieri and P. Blancafort

Molecular Therapy - Methods & Clinical Development, Vol.21(11), pp.592-606

2021

DOI: https://doi.org/10.1016/j.omtm.2021.04.009

Files and links (2)

pdf

CRISPR.pdfDownload View

Published (Version of Record) Open Access

url

Free to Read *No subscription requiredView

Abstract

Precise clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genetic and epigenetic manipulation of the immune response has become a promising immunotherapeutic approach towards combating tumorigenesis and tumor progression. CRISPR-based immunologic reprograming in cancer therapy comprises the locus-specific enhancement of host immunity, the improvement of tumor immunogenicity and the suppression of tumor immunoevasion. To date, the ex vivo re-engineering of immune cells directed to inhibit the expression of immune checkpoints or to express synthetic immune receptors (chimeric antigen receptor therapy) has shown success in some settings, such as in the treatment of melanoma, lymphoma, liver and lung cancer. However, advancements in nuclease-deactivated CRISPR-associated nuclease-9 (dCas9)-mediated transcriptional activation or repression and Cas13-directed gene suppression presents novel avenues for the development of tumor immunotherapies. In this review, the basis for development, mechanism of action and outcomes from recently published Cas9-based clinical trial (genetic editing) and dCas9/Cas13-based pre-clinical (epigenetic editing) data are discussed. Lastly, we review cancer immunotherapy-specific considerations and barriers surrounding use of these approaches in the clinic.

Details

Title: Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Authors/Creators: E. Alves (Author/Creator) - Harry Perkins Institute of Medical Research
S. Taifour (Author/Creator) - Harry Perkins Institute of Medical Research
R. Dolcetti (Author/Creator) - The University of Queensland
J. Chee (Author/Creator) - The University of Western Australia
A.K. Nowak (Author/Creator) - The University of Western Australia
S. Gaudieri (Author/Creator) - Vanderbilt University Medical Center
P. Blancafort (Author/Creator) - Harry Perkins Institute of Medical Research
Publication Details: Molecular Therapy - Methods & Clinical Development, Vol.21(11), pp.592-606
Publisher: Elsevier
Identifiers: 991005543427607891
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

132 File views/ downloads

78 Record Views

24 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.54 Molecular & Cell Biology - Genetics; 1.54.1401 Genome Editing
Web Of Science research areas: Medicine, Research & Experimental
ESI research areas: Biology & Biochemistry